Endo International PLC (ENDP) to Post Q2 2017 Earnings of $1.24 Per Share, Oppenheimer Holdings Forecasts
Endo International PLC (NASDAQ:ENDP) – Research analysts at Oppenheimer Holdings issued their Q2 2017 earnings per share estimates for shares of Endo International PLC in a research note issued to investors on Sunday. Oppenheimer Holdings analyst R. Vanjani anticipates that the firm will post earnings per share of $1.24 for the quarter. Oppenheimer Holdings has a “Market Perform” rating on the stock. Oppenheimer Holdings also issued estimates for Endo International PLC’s Q4 2017 earnings at $1.12 EPS.
A number of other research analysts also recently weighed in on ENDP. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a $40.00 price target on shares of Endo International PLC in a research note on Tuesday, July 26th. Leerink Swann reaffirmed a “market perform” rating and set a $22.00 price target on shares of Endo International PLC in a research note on Friday, September 23rd. Goldman Sachs Group Inc. initiated coverage on Endo International PLC in a research note on Monday, June 6th. They set a “neutral” rating and a $20.00 price target on the stock. Piper Jaffray Cos. set a $19.00 price target on Endo International PLC and gave the stock a “hold” rating in a research note on Tuesday, August 9th. Finally, Vetr raised Endo International PLC from a “hold” rating to a “buy” rating and set a $21.95 price target on the stock in a research note on Thursday, August 25th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and eleven have given a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $39.32.
Shares of Endo International PLC (NASDAQ:ENDP) opened at 22.53 on Tuesday. Endo International PLC has a one year low of $12.56 and a one year high of $72.85. The company’s market cap is $5.02 billion. The stock’s 50 day moving average price is $21.51 and its 200 day moving average price is $21.28.
Endo International PLC (NASDAQ:ENDP) last announced its quarterly earnings results on Monday, August 8th. The company reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.12. The firm had revenue of $921 million for the quarter, compared to analysts’ expectations of $873.50 million. Endo International PLC had a positive return on equity of 15.54% and a negative net margin of 25.90%. The business’s revenue was up 25.3% compared to the same quarter last year. During the same period in the prior year, the business posted $1.08 earnings per share.
Several large investors have recently modified their holdings of ENDP. Advantus Capital Management Inc increased its stake in shares of Endo International PLC by 2.4% in the second quarter. Advantus Capital Management Inc now owns 19,932 shares of the company’s stock worth $311,000 after buying an additional 461 shares during the period. Aperio Group LLC increased its stake in Endo International PLC by 1.7% in the first quarter. Aperio Group LLC now owns 43,200 shares of the company’s stock worth $1,216,000 after buying an additional 732 shares during the last quarter. Massmutual Trust Co. FSB ADV increased its stake in Endo International PLC by 7.0% in the first quarter. Massmutual Trust Co. FSB ADV now owns 11,377 shares of the company’s stock worth $320,000 after buying an additional 745 shares during the last quarter. Riverhead Capital Management LLC increased its stake in Endo International PLC by 5.5% in the first quarter. Riverhead Capital Management LLC now owns 32,435 shares of the company’s stock worth $913,000 after buying an additional 1,694 shares during the last quarter. Finally, Canada Pension Plan Investment Board increased its stake in Endo International PLC by 33.0% in the first quarter. Canada Pension Plan Investment Board now owns 9,019 shares of the company’s stock worth $254,000 after buying an additional 2,237 shares during the last quarter. Institutional investors own 96.64% of the company’s stock.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.